Publications

Warner Greene, MD, PhDThe brightening future of HIV therapeutics. View in: PubMed
Warner C. Greene, MD, PhDGreene WC. Redistricting the retroviral restriction factors. Nat Med. 2004 Aug; 10(8):778-80. View in: PubMed
Warner Greene, MD, PhDRedistricting the retroviral restriction factors. View in: PubMed
Warner C. Greene, MD, PhDWilliams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem. 2004 Oct 1; 279(40):42008-17. View in: PubMed
Warner Greene, MD, PhDProstratin antagonizes HIV latency by activating NF-kappaB. View in: PubMed
Warner C. Greene, MD, PhDChen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004 May; 5(5):392-401. View in: PubMed
Warner Greene, MD, PhDShaping the nuclear action of NF-kappaB. View in: PubMed
Warner C. Greene, MD, PhDBohuslav J, Chen LF, Kwon H, Mu Y, Greene WC. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem. 2004 Jun 18; 279(25):26115-25. View in: PubMed
Warner Greene, MD, PhDp53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. View in: PubMed
Warner C. Greene, MD, PhDO'Mahony AM, Montano M, Van Beneden K, Chen LF, Greene WC. Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem. 2004 Apr 30; 279(18):18137-45. View in: PubMed